Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

138.87 -4.11 (-2.87%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,455,806
Open 141.34
Bid (Size) 138.53 (1)
Ask (Size) 138.64 (1)
Prev. Close 142.98
Today's Range 136.01 - 141.52
52wk Range 75.56 - 148.15
Shares Outstanding N/A
Dividend Yield 1.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
New study suggests a potential link between Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, and NAION, a condition that can cause vision loss. Researchers urge further analysis and awareness for... 
Via Benzinga

Performance

YTD
+36.00%
+36.00%
1 Month
+2.40%
+2.40%
3 Month
+9.36%
+9.36%
6 Month
+34.02%
+34.02%
1 Year
+73.59%
+73.59%

More News

Read More
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Via Investor's Business Daily
The 7 Best Stocks to Buy in July 2024
Via InvestorPlace
Why Novo Nordisk Stock Is Slipping Today
Via The Motley Fool
Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock
Via Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
Via Investor's Business Daily
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
Via Investor's Business Daily
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing?
Via Chartmill
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Via MarketBeat
Exposures Product Safety
3 Breakout Biotech Stocks on Track to Double by 2032
Via InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Via Talk Markets
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Via The Motley Fool
This Is Massive News for Eli Lilly Investors
Via The Motley Fool
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stock Market Rally Powers To Fresh Highs; Carnival, Micron, Nike In Focus: Weekly Review
Via Investor's Business Daily
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Via Benzinga
Volkswagen Puts Our Rivian Bet In The Black: The Pros And Cons Of Trading Options Versus Stocks
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.